Amazon Explores AI Content Marketplace With Media Publishers 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
NEW YORK, April 09, 2018 -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries, today announced that its President & CEO Gerald E. Commissiong will present a corporate overview at The Microcap Conference on April 10, 2018 at 9:30am in Track 1 at the JW Marriott Essex House in New York, NY.
The presentation will be webcast live at http://www.investorcalendar.com/event/27690 and will be archived for 90 days following the presentation. Interested investors may contact the Company by email at [email protected] or by calling and leaving a message at 917-686-5317.
The Company's CEO Gerald Commissiong, and interim-COO/CFO Barney Monte have remaining availability for one-on-one meetings with investors on Tuesday April 10, 2018.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS), a JLABS alumnus company, is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. The Company also re-acquired rights to Alzheimer's blood diagnostic LymPro Test, MSPrecise and NuroPro.
For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook,LinkedIn,Twitter and Google+.
Amarantus Investor and Media Contact:
Howard Gostfrand
American Capital Ventures, Inc.
Office: 305-918-7000
Email: [email protected]
Source: Amarantus Bioscience Holdings, Inc.
